ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Sight Sciences Inc

Sight Sciences Inc (SGHT)

8.28
-0.03
( -0.36% )
Updated: 10:17:18

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.504.907.400.006.150.000.00 %00-
5.001.753.601.572.6750.000.00 %01-
7.500.651.150.800.900.000.00 %022-

Empower your portfolio: Real-time discussions and actionable trading ideas.

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.750.000.000.000.00 %00-
5.000.000.750.000.000.000.00 %00-
7.500.450.300.450.3750.000.00 %010-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
APVOAptevo Therapeutics Inc
$ 0.6472
(93.19%)
158.73M
HUBCWHub Cyber Security Ltd
$ 0.025
(51.52%)
17.01k
ADTXAditxt Inc
$ 2.31
(44.38%)
22.93M
SHIMShimmick Corporation
$ 2.91
(40.58%)
11.3M
LCFYLocafy Ltd
$ 7.419
(36.13%)
18.37M
ASLNASLAN Pharmaceuticals Ltd
$ 0.711
(-35.95%)
1.57M
SAVACassava Sciences Inc
$ 9.14
(-32.45%)
8.83M
FIVEFive Below Inc
$ 81.95
(-19.71%)
4.46M
SCNIScinai Immunotherapeutics Ltd
$ 4.281
(-19.38%)
86.02k
ADVMAdverum Biotechnologies Inc
$ 7.54
(-15.47%)
1.05M
APVOAptevo Therapeutics Inc
$ 0.64
(91.04%)
158.92M
NVDANVIDIA Corporation
$ 118.935
(-5.88%)
101.8M
VERBVerb Technology Company Inc
$ 0.11765
(1.07%)
60.44M
SQQQProShares UltraPro Short QQQ
$ 7.9601
(6.70%)
52.23M
INTCIntel Corporation
$ 36.245
(5.55%)
38.65M

SGHT Discussion

View Posts
RC_702 RC_702 1 hour ago
Re: the buyout you speculated about

Iโ€™m guessing that Alison Bouerlein, CFO
Jeremy Hayden , David Badawi, CTO, Paul Badawi CEO, and Sam Park CTO who are officers of sght did not know about the merger either.
They all sold shares July 1, 2 2024

47,780 shares at 5.42 to 6.21 average price per share
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 12 hours ago
they're
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 18 hours ago
Oh no, not another UP day!! How many am I supposed to endure?

UP $0.49
+6.27%

ANOTHER 11 month high closing PPS!

Boy- those analysts sure do know what their talking about, don't they!?!?
๐Ÿ‘๏ธ0
RC_702 RC_702 2 days ago
I guess they donโ€™t know about the buyout:


According to marketbeat:


UPSIDE/ DOWNSIDE
27.1% Downside
$5.70 Price Target

SHORT INTEREST
Bearish
4.09% of Float Sold Short

ANALYST RATING
Hold
2.00 Rating Score

(Sight Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 5 hold ratings, and 1 sell rating.)

INSIDER TRADING
Selling Shares
$290,061 Sold Last Quarter

Overall marketrank
0.50 out of 5 stars
๐Ÿ‘๏ธ0
RC_702 RC_702 2 days ago
What happened?

Sight Sciences sets terms for IPO, to raise up to $160.5 million
Published: July 8, 2021 at 6:37 a.m. ET

Sight Sciences Inc. has set terms of its initial public offering, which could value the California-based ophthalmology and optometry company at up to $971.7 million. The company is looking to raise up to $160.54 million, as it is offering 6.98 million shares in the IPO, which is expected to price between $20 and $23 a share.
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 2 days ago
LOL

Up nearly 3%

Closed at the 11 month high pps
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 2 days ago
lol
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 2 days ago
I put more weight into my own projection- that SGHT will be acquired by a larger optical device company, like Alcon, against whom SGHT was recently awarded damages for patent infringement.

https://www.healio.com/news/ophthalmology/20240430/sight-sciences-awarded-34-million-in-patent-infringement-case-against-alcon
๐Ÿ‘๏ธ0
RC_702 RC_702 2 days ago
Hereโ€™s where I got the information:

Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT ยท IEX Real-Time Price ยท USD

Price Target
5.60 (-27.18%)
๐Ÿ‘๏ธ0
RC_702 RC_702 2 days ago
Not my analysis, just researching what various experts have suggested about the potential stock movements of sght.

Three different sources have said not to buy and multiple sources have said year price around $6.

What do you think about the fact that the projected profitability is three years away at best?
๐Ÿ‘๏ธ0
RC_702 RC_702 2 days ago
Perhaps JP Morgen and others that dumped all their stock was because of this:

Financial Efficiency
Return on equity (ROE) is -44.50% and return on invested capital (ROIC) is -38.09%.

I believe that would be a good call
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 2 days ago
That makes so much sense

7 analysts have a target of $5.60, which is $2 BELOW the current PPS, and yet, the 7 analysts recommending holding?

So- they recommend holding so as to lock in a 30% LOSS?
BRILLIANT!!!!

RC_702
Re: None
Monday, July 15, 2024 9:25:07 AM
Post# of 80 Go
Analyst Forecast
According to 7 analysts, the average rating for SGHT stock is "Hold." The 12-month stock price forecast is $5.6, which is a decrease of -26.41% from the latest price.

Price Target
$5.6
(-26.41% downside)
Analyst Consensus: Hold[/quote]
๐Ÿ‘๏ธ0
RC_702 RC_702 2 days ago
Analyst Forecast
According to 7 analysts, the average rating for SGHT stock is "Hold." The 12-month stock price forecast is $5.6, which is a decrease of -26.41% from the latest price.

Price Target
$5.6
(-26.41% downside)
Analyst Consensus: Hold
๐Ÿ‘๏ธ0
RC_702 RC_702 2 days ago
Before you buy stock in Sight Sciences, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy nowโ€ฆ and Sight Sciences wasnโ€™t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
๐Ÿ‘๏ธ0
RC_702 RC_702 2 days ago
Perhaps JP and others dumped their shares because of this:

Sight Sciences Insiders Are Selling The Stock
Over the last three months, we've seen significant insider selling at Sight Sciences. In total, insiders sold US$244k worth of shares in that time, and we didn't record any purchases whatsoever.

I guess thatโ€™s what you could consider a good call
๐Ÿ‘๏ธ0
RC_702 RC_702 2 days ago
Sorry, but it was not my call. Iโ€™m not an expert but I can read what the experts have stated

I guess youโ€™re referring to JP Morgan dumping all of their shares recently being a good call
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 2 days ago
GOOD CALL!!!
12 Month Price Target usd 6.10
Based on 4 analysts
Price Volatility. High
Last updated: 6/12/2024
On 6/12 the PPS closed @ $6.86

On Friday the PPS closed @ $7.61

That's more than a 10% gain in 1 month

Oh, and BTW, a 25% gain for my $2.98 shares.
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 2 days ago
it seems they were all wrong to sell and forecast lower
Closed on Friday at an 11 month high PPS

I'm laughing all the way to the bank
1 YEAR CHART
๐Ÿ‘๏ธ0
RC_702 RC_702 4 days ago
Or perhaps it was:

Operating Income % is Gross Profit minus Operating Expenses. Shown as a percentage of Revenue. A good indicator of profitability. Higher is better.

SGHT OI
2023 - 77.06 %
2022 - 117.70%

Or:

Net Profit % shows how much of each dollar in Revenue translates into Profit. Shown as a percentage of Revenue. Higher is better.

SGHT Net Profit
2023 -68.53%
2022 - 120.90%

And analysts say that they are not going to be profitable for at least three years
๐Ÿ‘๏ธ0
RC_702 RC_702 4 days ago
Perhaps it was this:

12 Month Price Target usd 6.10
Based on 4 analysts
Price Volatility. High
Last updated: 6/12/2024
Industry Recommendation. Hold
๐Ÿ‘๏ธ0
RC_702 RC_702 4 days ago
What do they know about the company that made them dump the stock recently?

JPMorgan Chase decreased stake by 12.86% to
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 5 days ago
LMAO!!!

UP 30% since your post.
๐Ÿ‘๏ธ0
RC_702 RC_702 2 weeks ago
Earnings Trend: SGHT is unprofitable, and losses have increased over the past 5 years at a rate of 15.5% per year.
๐Ÿ‘๏ธ0
RC_702 RC_702 2 weeks ago
Insider trading , why did:
D1 capital partners LD on 26 Dec23
Sell $16,712,931 of sight sciences?
Entity: company
Shares: 2,852,036
Max Price: $5.86
๐Ÿ‘๏ธ0
RC_702 RC_702 2 weeks ago
Sight Sciences Insiders Are Selling The Stock
Over the last three months, we've seen significant insider selling at Sight Sciences. In total, insiders sold US$244k worth of shares in that time, and we didn't record any purchases whatsoever.
Yahoo finance June 14, 2024
๐Ÿ‘๏ธ0
RC_702 RC_702 2 weeks ago
Sight Sciences Insiders Are Selling The Stock
Over the last three months, we've seen significant insider selling at Sight Sciences. In total, insiders sold US$244k worth of shares in that time, and we didn't record any purchases whatsoever.
Yahoo finance June 14, 2024
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 month ago
SGHT under $10
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 1 month ago
Wow- somebody took a bunch of profit in the last minutes. First down day is quite a while
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 1 month ago
And another up day.
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 1 month ago
First time SGHT closed above $7 in over 6 months!!!
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 1 month ago
She broke through seven dollars. very strong volume today. So bright I gotta wear shades
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 2 months ago
Good news...

creates big gains. Blue skies ahead. My $2.98's have doubled+
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 2 months ago
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (โ€œSight Sciences,โ€ or the โ€œCompanyโ€), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patientsโ€™ lives, today announced the publication of the twelve-month results from the SAHARA trial.

Patients previously treated with Restasis® (cyclosporine ophthalmic emulsion 0.05%) prescription eyedrops (โ€œRestasisโ€) had additional clinically meaningful improvements in the signs and symptoms of dry eye disease (โ€œDEDโ€) when crossed over to TearCare. These improvements persisted for six months through month twelve without continued Restasis use.

โ€œPhase 2 of the RCT again demonstrates the clinical effectiveness of TearCare. It also shows that effectiveness appears to be the same whether or not a patient has had prior treatment with Restasis, demonstrating that similar results could be expected when TearCare is used as a primary or secondary treatment for DED,โ€ said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences.

Phase 1 of the SAHARA RCT included 345 subjects at 19 sites in 11 states randomized 1:1 to either TearCare or Restasis1. In Phase 2 of the SAHARA RCT, 163 patients who had been randomized and treated with Restasis during phase 1 were crossed over to TearCare at the six-month visit and followed for six months through Month 12 of the study.

Data from the first six months of the SAHARA RCT demonstrated that TearCare, an interventional eyelid procedure for DED, was superior at all measured time points to twice daily use of Restasis for the improvement of tear break up time (โ€œTBUTโ€), the trialโ€™s primary dry eye signs endpoint and a key measure of tear stability1. TearCare was superior to Restasis in multiple other objective measures of dry eye, and demonstrated clinically meaningful improvements in several symptoms that matched or surpassed Restasis at all measured time points.

The aim of phase 2, undertaken in months six through twelve, was to demonstrate that cessation of Restasis followed by a single TearCare procedure would result in improved signs and symptoms for patients beyond what was achieved with six months of Restasis.
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 2 months ago
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the results as published in the journal Clinical Ophthalmology of a new analysis of the ROMEO (Retrospective, Observational, Multicenter Evaluation of OMNI) study data. This new analysis evaluated the association between the severity of glaucoma and the intraocular pressure ("IOP") and medication outcomes for patients treated with the OMNI Surgical System ("OMNI"). OMNI enables a procedure intended to restore aqueous outflow of glaucomatous eyes by addressing the three areas of outflow resistance associated with the disease.

The findings suggest that ab interno canaloplasty coupled with trabeculotomy using OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma patients as it was in mild and moderate glaucoma patients. This data challenges the belief that advanced disease stage is a barrier to successful treatment outcomes for minimally invasive glaucoma surgery ("MIGS").

"There had been some debate about the efficacy of MIGS in advanced glaucoma patients, with speculation that prolonged disease may cause irreversible harm to the distal outflow pathway," said Dr. Jaime E. Dickerson, Jr., Vice President of Medical and Clinical Affairs at Sight Sciences. "The current study suggests that treatment with OMNI technology, which has a strong safety profile and proven durability, is still effective in patients with more extensive visual field damage."

ROMEO was an Institutional Review Board ("IRB") approved retrospective case series conducted at eleven ophthalmology practices in the United States. Participants were mainly primary open-angle glaucoma patients (122 of 129, or 95%) who had undergone the implant-free OMNI procedure, which has been cleared by the FDA for canaloplasty followed by ab interno trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma, either combined with cataract surgery or as a standalone procedure.

Eyes were categorized based on visual field mean deviation ("MD"), with participants assigned to a group with severity rated as mild (n=79, median MD -2.7 dB), moderate (n=42, median MD -8.0 dB) or advanced (n=6, median MD -13.3). The study compared outcomes at 12 months.

Key findings reported in the study include:

Significant reductions in both IOP and IOP-reducing medications were observed.
The majority of eyes (70%) experienced a reduction in IOP at Month 12, with most achieving levels of 18 mmHg or less (92%).
The percentage of IOP reduction was consistent across severity groups, with month 12 mean IOP ranging between 14 mmHg and 16 mmHg.
Medication reductions were observed across all severity groups, with the majority of patients showing a reduction of at least 1 medication (50% to 69%), indicating the effectiveness of the treatment approach.
Regression analysis found no significant relationship between month 12 IOP and visual field loss, suggesting treatment outcomes were consistent irrespective of disease severity.
"Clinical trials and real-world results continue to demonstrate favorable OMNI treatment outcomes across different stages of glaucoma," said Paul Badawi, Co-Founder and CEO of Sight Sciences. "These findings reinforce our dedication to offering effective treatment options for glaucoma patients at every stage of the disease and also fuel our initiatives to continue reimagining eyecare with transformative technology and an interventional mindset."
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 2 months ago
Looking awesome! Excellent quarterly conference call. PPS is strong and the future should be most favorable. +$6 is a few pennies away. +$10 this summer seems reasonable.
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 3 months ago
Great news!
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 3 months ago
News of a settlement? Basis for yesterday's gain?
04/23/2024 STATEMENT Offer of Proof Regarding the Economic Comparability of the Glaukos Settlement Agreement by Alcon Inc.,
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 3 months ago
Beautiful close above $6.
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 3 months ago
Jury selection begins pretty soon between Alcon and sight sciences. SGHT has very good sales and clinically proven efficacy. Seems to me that the quickest fix for Alconโ€™s problems is to buy sight sciences, lock, stock, and barrel. Alcon gets two great products and whatever sight sciences has in development. Perhaps most importantly, an acquisition makes Alcon's legal problems go away. Alcon's is looking at huge retroactive and ongoing royalties due to Sight Sciences, if the jury decides against Alcon.
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 3 months ago
SGHT: The potential expansive applications for their tech. go way beyond mere 'DRY EYES', per se.
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 3 months ago
SGHT: We'll see what their 'Industry' thinks about it come 4-5-24. (Their Firm is in Menlo Park --- i.e., "Silicon Valley".)
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 3 months ago
โ€œLong-term data is key in the selection of a surgical treatment,โ€ said Arkadiy Yadgarov, MD, of Omni Eye Services of Atlanta, GA. โ€œThe 12-month GEMINI trial demonstrated efficacy of the OMNI procedure combined with cataract surgery for IOP and medication reduction in mild-to-moderate glaucoma.1,2 This extension of the trial shows that these positive 12-month outcomes were sustained through 36 months.โ€

๐Ÿ‘๏ธ0
Southern Gal Southern Gal 3 months ago
โ€œIn phase 1 of the SAHARA trial, we found the interventional TearCare procedure provided statistically superior and sustained improvement in tear break-up time and multiple measures of meibomian gland secretion when compared to treatment with Restasis.3 In phase 2 (cross-over) of the study, we found that a single TearCare procedure improved signs and symptoms for patients beyond what was achieved with six months of Restasis.โ€
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 3 months ago
SGHT: (See their PR, below) Their CEO seems pretty excited about their looming presentation to fix Dry Eye disorder, inter alia.
https://finance.yahoo.com/news/sight-sciences-announces-results-three-200500426.html
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 3 months ago
Up huge after hours following good news
Canโ€™t wait for tomorrow morning.
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 4 months ago
Up again
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 4 months ago
Looking strong. $5
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 5 months ago
Q will be discussed early March. Now that reimbursement is no longer an issue, blue sky ahead.
๐Ÿ‘๏ธ0
Dubster watching Dubster watching 5 months ago
Well done sister! Gl
๐Ÿ‘๏ธ0
Southern Gal Southern Gal 5 months ago
Bought more near $4
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock